Drug Profile
Trans-sodium crocetinate - Diffusion Pharmaceuticals
Alternative Names: Crocetin sodium salt; Sodium crocetinate; Trans sodium crocetinate; Transcrocetinate sodium; TSC; TSC-cpdLatest Information Update: 21 Nov 2019
Price :
$50
*
At a glance
- Originator Office of Naval Research; University of Virginia
- Developer Diffusion Pharmaceuticals
- Class Antineoplastics; Carotenoids; Neuroprotectants; Radiation-sensitising agents; Small molecules; Vascular disorder therapies
- Mechanism of Action Oxygen compound modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Glioblastoma
- Phase II Stroke
- Preclinical Brain metastases; Pancreatic cancer
- Discontinued Peripheral arterial disorders
Most Recent Events
- 11 Nov 2019 The Data Safety Monitoring Board recommends continuation of the INTACT trial using 1.5 mg/kg of Trans-sodium crocetinate
- 22 Aug 2019 Phase-II clinical trials in Stroke in USA (IV) (NCT03763929)
- 11 Feb 2019 Diffusion Pharmaceuticals, in collaboration with the University of California Los Angeles and the University of Virginia, plans a phase II PHAST-TSC (Pre-Hospital Ambulance Stroke Trial - TSC) trial for Stroke in USA in the second quarter of 2019